Skip to main content
profile image
Selected Works of Carlo B. Bifulco, M.D.
Article
Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies
Blood (2017)
  • Michael P Rettig, Washington University in St. Louis
  • John Godwin, Providence Cancer Center, Portland, OR
  • Norbert Vey, Clinical Hematology, Paoli-Calmettes Institute, Marseille, France
  • Bernard Fox, Providence Cancer Center, Portland, OR
  • Carmen Ballesteros-Merino, Providence Cancer Center, Portland, OR
  • Carlo B Bifulco, Providence Cancer Center, Portland, OR
  • Daner Li, MacroGenics, Inc., Rockville, MD
  • Daniel Primo, Parque Científico de Madrid, Vivia Biotech, Madrid, Spain
  • Joan Ballesteros, Parque Científico de Madrid, Vivia Biotech, Madrid, Spain
  • Jichao Sun, MacroGenics, Inc., Rockville, MD
  • Helene Lelièvre, Centre de Recherche en Cancérologie de Marseille, Servier, Suresnes, France
  • Jan Baughman, MacroGenics, Inc., Rockville, MD
  • Ross La Motte-Mohs, MacroGenics, Inc., Rockville, MD
  • John Muth, MacroGenics, Inc., Rockville, MD
  • Paul Moore, MacroGenics, Inc., Rockville, MD
  • Ezio Bonvini, MacroGenics, Inc., Rockville, MD
  • Jon Wigginton, MacroGenics, Inc., Rockville, MD
  • John F DiPersio, Washington University in St. Louis
  • Jan Davidson-Moncada, MacroGenics, Inc., Rockville, MD
Link
Disciplines
Publication Date
December 7, 2017
DOI
10.1182/BLOOD.V130.SUPPL_1.1365.1365
Citation Information
Michael P Rettig, John Godwin, Norbert Vey, Bernard Fox, et al.. "Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies" Blood Vol. 130 (2017) p. 1365 - 1365
Available at: http://works.bepress.com/carlo-bifulco/73/